Comments on India’s draft biotech patent guidelines posted

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Comments on India’s draft biotech patent guidelines posted

The India Patent Office has released public feedback to its draft guidelines for the examination of biotechnology patents

The guidelines were released on December 11 2013 with a public comment period until January 11. The Patent Office received comments from Indian biotechnology firms, patent law firms, and groups such as the Organisation of Pharmaceuticals Producers of India (OPPO), the Biotechnology Industry Organization (BIO) and even the Japan Intellectual Property Association.

The Spicy IP blog described the publication as a “welcome development”.

The introduction to the draft guidelines state that they are intended to address serious concerns concerning “novelty, obviousness, industrial applicability, extent of disclosure and clarity in claims” which often arise in biotechnology patents. The guidelines also note that there are issues unique to biotechnology, “such as those relating to moral and ethical concerns, environmental safety, issues relating to patenting of ESTs (expressed sequence tags) of partial gene sequences, cloning of farm animals, stem cells, [and] gene diagnostics”.

Representatives of rights holders have expressed concern that the guidelines take too strict a view on patentability. OPPI, the industry group for large international pharmaceutical companies, said in its submission that the guidelines used an overly broad definition of obviousness. It also said that some of the provisions lacked clarity, that some limitations such as the prohibition of patenting methods of treatment appear to be broader in the guidelines’ examples than in the guideline text.

Similarly, Anand & Anand, who represents a number of large international pharmaceutical companies, stressed in its comments that the draft outlines do not have the force of law and argue that some of the illustrations are inconsistent with Patent Office practice.



more from across site and SHARED ros bottom lb

More from across our site

Partner Ginevra Righini explains how she secured victory for the Comité Champagne in its fight against an EUTM application for ‘Nero Champagne’
Volkan Hamamcıoğlu joins us for our ‘Five minutes with’ series to discuss meditation, tackling deadlines, and taking inspiration from Hamlet
A $110 million US verdict against Apple and an appellate order staying a $39 million trademark infringement finding against Amazon were also among the top talking points
Attorneys are watching how AI affects trademark registrations and whether a SCOTUS ruling from last year will have broader free speech implications
Patent lawyers explain why they will be keeping an eye on the implications of a pharma case and on changes at the USPTO in the second half of 2025
The insensitive reaction to a UK politician crying on TV proves we have a long way to go before we can say we are tackling workplace wellbeing
Adrian Percer says he was impressed by the firm’s work on billion-dollar cases as well as its culture
In our latest interview with women IP leaders, Catherine Bonner at Murgitroyd discusses technology, training, and teaching
Developments included an update in the VAR dispute between Ballinno and UEFA, the latest CMS updates, and a swathe of market moves
The LMG Life Sciences Americas Awards is thrilled to present the 2025 shortlist
Gift this article